← Leaderboards
Ruben D Carrasco
Dana-Farber Cancer Institute
$9,710,954
Attributed
$9,710,954
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,710,954 · 8
By mechanism
R01$8,102,135 · 4
K08$623,245 · 1
P01$570,864 · 2
R21$414,710 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsIn VivoTumorHematologic NeoplasmsEffective TherapyS LymphomaCellsIn VitroCell LineProteomicsSignal TransductionMediatingPathogenesisDesignPlayBcl9 GenePathway InteractionsPatient-Focused OutcomesBaseMultiple MyelomaOverexpressionMolecularComplexBone Marrow
Grant awards (31)
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy$550,877
R01 · FY2025 · CA · contact PI
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies$414,729
R01 · FY2025 · CA · contact PI
Pathology$116,547
P01 · FY2025 · CA · contact PI
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy$523,333
R01 · FY2024 · CA · contact PI
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies$427,785
R01 · FY2024 · CA · contact PI
Pathology$106,386
P01 · FY2024 · CA · contact PI
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy$539,860
R01 · FY2023 · CA · contact PI
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies$436,841
R01 · FY2023 · CA · contact PI
Pathology$114,211
P01 · FY2023 · CA · contact PI
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy$539,855
R01 · FY2022 · CA · contact PI
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies$433,679
R01 · FY2022 · CA · contact PI
Pathology$114,186
P01 · FY2022 · CA · contact PI
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy$569,443
R01 · FY2021 · CA · contact PI
Pathology$119,534
P01 · FY2021 · CA · contact PI
Validating the eCyPA/CD147 signaling complex for myeloma therapy$382,977
R01 · FY2019 · CA · contact PI
Development of molecular probes to investigate and drug the oncogenic Wnt/?-catenin/BCL9/B9L transcriptional complex$185,134
R21 · FY2019 · CA · contact PI
Validating the eCyPA/CD147 signaling complex for myeloma therapy$394,823
R01 · FY2018 · CA · contact PI
Development of molecular probes to investigate and drug the oncogenic Wnt/?-catenin/BCL9/B9L transcriptional complex$229,576
R21 · FY2018 · CA · contact PI
Validating the eCyPA/CD147 signaling complex for myeloma therapy$394,823
R01 · FY2017 · CA · contact PI
Validating the eCyPA/CD147 signaling complex for myeloma therapy$394,823
R01 · FY2016 · CA · contact PI
Validating the eCyPA/CD147 signaling complex for myeloma therapy$393,715
R01 · FY2015 · CA · contact PI
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics$335,807
R01 · FY2014 · CA · contact PI
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics$325,422
R01 · FY2013 · CA · contact PI
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics$346,193
R01 · FY2012 · CA · contact PI
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics$346,193
R01 · FY2011 · CA · contact PI
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics$350,957
R01 · FY2010 · CA · contact PI
Novel System to Study Telomere Dynamics in Hemotopoiesis$124,689
K08 · FY2005 · AG
Novel System to Study Telomere Dynamics in Hemotopoiesis$124,689
K08 · FY2004 · AG
Novel System to Study Telomere Dynamics in Hemotopoiesis$124,689
K08 · FY2003 · AG
Novel System to Study Telomere Dynamics in Hemotopoiesis$124,689
K08 · FY2002 · AG
Novel System to Study Telomere Dynamics in Hemotopoiesis$124,489
K08 · FY2001 · AG